| Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 21869539 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To determine whether miglitol administration improves glycemic control and reduces the frequency of hypoglycemia in type 1 diabetes mellitus (T1DM) patients treated with intensive insulin therapy, we analyzed the effect of miglitol on daily insulin doses, body weight, hypoglycemia, and incretin hormone responses during meal tolerance tests (MTT). Eleven T1DM subjects (21-77 years) undergoing intensive insulin therapy, took 25 mg (weeks 0-4) and 50 mg miglitol (weeks 4-12) thrice daily, immediately before meals. At weeks 0 and 12, 9 of 11 subjects underwent MTT. In present study, mean HbA1c, glycoalbumin, and 1,5-anhydroglucitol levels were significantly improved. The blood glucose level 1 h after dinner was significantly lower at week 12 than at week 0 (p = 0.008). From week 0 to 12, there was a significant decrease in the body mass index (BMI; p = 0.0051), frequency of preprandial hypoglycemic events (p = 0.012), and daily bolus insulin dosage (p = 0.018). The change in active glucagon-like peptide-1 (GLP-1) at 120 min significantly increased at week 12 (p = 0.015). The change in total glucose-dependent insulinotropic peptide (GIP) significantly decreased in the MTT at week 12. These results demonstrate that addition of miglitol on intensive insulin therapy in T1DM patients has beneficial effects on reducing BMI, bolus and total insulin dosage, and frequency of preprandial hypoglycemic events. MTT findings suggest that this combination therapy improves blood glucose control by delaying carbohydrate absorption and modifying the responses of incretins, GIP, and GLP-1. |
| | |
Authors:
|
Etsuko Nagai; Tomoyuki Katsuno; Jun-Ichiro Miyagawa; Kosuke Konishi; Masayuki Miuchi; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Kazuki Murai; Tomoya Hamaguchi; Mitsuyoshi Namba |
Related Documents
:
|
2520259 - Cardiovascular disease in genotypes for obesity and diabetes. 6341759 - Plasma glucose and insulin responses to oral glucose in nonobese subjects and patients ... 21868779 - Effects of exenatide on measures of {beta}-cell function after 3 years in metformin-tre... 10490799 - Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated o... 8943799 - Obesity and metabolic complications: contribution of dehydroepiandrosterone and other s... 12453909 - Endothelin contributes to basal vascular tone and endothelial dysfunction in human obes... 11309739 - Vitrectomy for refractory diabetic macular edema. 16635049 - Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetic... 18487479 - Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-ba... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2011-08-26 |
Journal Detail:
|
Title: Endocrine journal Volume: 58 ISSN: 1348-4540 ISO Abbreviation: Endocr. J. Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-11-01 Completed Date: 2012-02-23 Revised Date: 2012-05-03 |
Medline Journal Info:
|
Nlm Unique ID: 9313485 Medline TA: Endocr J Country: Japan |
Other Details:
|
Languages: eng Pagination: 869-77 Citation Subset: IM |
Affiliation:
|
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. e-nagai@hyo-med.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Deoxynojirimycin
/
administration & dosage,
adverse effects,
analogs & derivatives*,
therapeutic use Adult Aged Deoxyglucose / blood Diabetes Mellitus, Type 1 / blood, drug therapy* Drug Therapy, Combination / adverse effects Enzyme Inhibitors / administration & dosage, adverse effects, therapeutic use Gastric Inhibitory Polypeptide / blood Glucagon-Like Peptide 1 / blood Hemoglobin A, Glycosylated / analysis Humans Hyperglycemia / prevention & control* Hypoglycemia / prevention & control* Hypoglycemic Agents / administration & dosage, adverse effects, therapeutic use* Incretins / blood* Insulin / administration & dosage*, adverse effects, therapeutic use Male Middle Aged Serum Albumin / analysis Weight Loss / drug effects Young Adult alpha-Glucosidases / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Incretins; 0/Insulin; 0/Serum Albumin; 0/glycosylated serum albumin; 0/hemoglobin A1c protein, human; 154-17-6/Deoxyglucose; 154-58-5/1,5-anhydroglucitol; 19130-96-2/1-Deoxynojirimycin; 59392-49-3/Gastric Inhibitory Polypeptide; 72432-03-2/miglitol; 89750-14-1/Glucagon-Like Peptide 1; EC 3.2.1.20/alpha-Glucosidases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Functional characterization of insulin receptor gene mutations contributing to Rabson-Mendenhall syn...
Next Document: Evaluation of Low-contrast Detectability in Low-dose Chest Computed Tomography.